TY - JOUR
T1 - Serum levels of per- and polyfluoroalkyl substances alternatives and blood pressure by sex status
T2 - Isomers of C8 health project in China
AU - Mi, Xin
AU - Yang, Yun Qing
AU - Zeeshan, Mohammed
AU - Wang, Zhi Bin
AU - Zeng, Xiao Yun
AU - Zhou, Yang
AU - Yang, Bo Yi
AU - Hu, Li Wen
AU - Yu, Hong Yao
AU - Zeng, Xiao Wen
AU - Liu, Ru Qing
AU - Dong, Guang Hui
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China ( 81950410633 , 81972992 , 81872582 , 81872583 ), the Science and Technology Program of Guangzhou (201807010032, 201803010054), National Key Research and Development Program of China ( 2018YFC1004300 , 2018YFE0106900 ), Fundamental Research Funds for the Central Universities ( 19ykjc01 , 17ykpy14 , 17ykpy16 ),and Natural Science Foundation of Guangdong Province ( 2019A050510017 , 2018B030312005 , 2018B05052007 , 2017A090905042 ).
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/12
Y1 - 2020/12
N2 - Several in vitro and in vivo studies have demonstrated the toxicity of perfluoroalkyl and polyfluoroalkyl substances (PFASs) alternatives, however, relevant epidemiological findings remain to be performed. In addition, the association between PFASs alternatives and blood pressure has not been explored. To address this gap, we quantified serum levels of alternatives and legacy PFAS in 1273 healthy Chinese, aged 34–94 years, from “isomers of C8 health project”. Our results showed that an increase of serum PFASs levels was correlated with elevated blood pressure and higher prevalence of hypertension: per natural log unit (ng/mL) increase of 6:2 chlorinated polyfluorinated ether sulfonic acids (Cl-PFESA) elevated 1.31 (95%CI: 0.13, 2.50) mmHg of diastolic pressure (DBP). Adjusted odds ratios (aORs) for hypertension with per natural log increase of 6:2 and 8:2 Cl-PFESA were 2.57 (95%CI: 1.86, 3.56) and 1.18 (95%CI: 1.06, 1.32), respectively. When stratified by sex, the effects of PFASs alternatives on increased blood pressure and hypertension were stronger in women. Meanwhile, the association between 6:2 Cl-PFESA (aOR = 6.81; 95%CI: 3.54, 13.09) and hypertension was stronger than perfluorooctanoic acid (PFOA) (aOR = 2.32, 95%CI: 1.38, 3.91) in women. In conclusion, our pilot study demonstrates that serum concentrations of PFASs alternatives are positively associated with blood pressure. Moreover, women seem to be more susceptible, and alternatives exhibited stronger effects than legacy PFASs.
AB - Several in vitro and in vivo studies have demonstrated the toxicity of perfluoroalkyl and polyfluoroalkyl substances (PFASs) alternatives, however, relevant epidemiological findings remain to be performed. In addition, the association between PFASs alternatives and blood pressure has not been explored. To address this gap, we quantified serum levels of alternatives and legacy PFAS in 1273 healthy Chinese, aged 34–94 years, from “isomers of C8 health project”. Our results showed that an increase of serum PFASs levels was correlated with elevated blood pressure and higher prevalence of hypertension: per natural log unit (ng/mL) increase of 6:2 chlorinated polyfluorinated ether sulfonic acids (Cl-PFESA) elevated 1.31 (95%CI: 0.13, 2.50) mmHg of diastolic pressure (DBP). Adjusted odds ratios (aORs) for hypertension with per natural log increase of 6:2 and 8:2 Cl-PFESA were 2.57 (95%CI: 1.86, 3.56) and 1.18 (95%CI: 1.06, 1.32), respectively. When stratified by sex, the effects of PFASs alternatives on increased blood pressure and hypertension were stronger in women. Meanwhile, the association between 6:2 Cl-PFESA (aOR = 6.81; 95%CI: 3.54, 13.09) and hypertension was stronger than perfluorooctanoic acid (PFOA) (aOR = 2.32, 95%CI: 1.38, 3.91) in women. In conclusion, our pilot study demonstrates that serum concentrations of PFASs alternatives are positively associated with blood pressure. Moreover, women seem to be more susceptible, and alternatives exhibited stronger effects than legacy PFASs.
KW - Blood pressure
KW - PFASs alternatives
KW - Perfluoroalkyl and polyfluoroalkyl substances (PFASs)
UR - http://www.scopus.com/inward/record.url?scp=85088400636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088400636&partnerID=8YFLogxK
U2 - 10.1016/j.chemosphere.2020.127691
DO - 10.1016/j.chemosphere.2020.127691
M3 - Article
C2 - 32717511
AN - SCOPUS:85088400636
SN - 0045-6535
VL - 261
JO - Chemosphere
JF - Chemosphere
M1 - 127691
ER -